Effect of hyperbaric oxygen (HBO) therapy on kidney function in metabolic syndrome (MetS) patients
Hyperbaric oxygen (HBO) therapy
DOI:
https://doi.org/10.59747/smjidisurabaya.v1i2.32Keywords:
hyperbaric oxygen therapy, kidney disease, metabolic syndrome, renal hypoxiaAbstract
Background: Hyperbaric Oxygen (HBO) therapy is the therapy of inhaling 100% pure oxygen in a hyperbaric chamber of more than 1 absolute atmosphere. Currently, the use of hyperbaric oxygen therapy is increasingly widespread, not only for decompression sickness and diving problems. But it has been used for clinical therapy, cosmetics, and geriatric care. The American Food and Drug Administration (FDA) has also confirmed various clinical indications, especially those related to metabolic syndromes such as Diabetes Mellitus (DM) and Diabetic Foot Ulcers (DFU). But the use of Hyperbaric Oxygen Therapy for kidney disease has not been fully study yet. Purpose: Here we summarized the scientific reason to use this therapy as adjuvant for patients with chronic kidney disease due to metabolic syndrome. Opinion: Several benefits of HBO has been reported such as reducing oxidative stress, alleviate vascular dysfunction and amyloid burden, ischemia and reperfusion injury, Increased NO production, and suggested to be useful as an adjuvant therapy in T2DM suspected with chronic kidney disease (CKD), as HBO therapy decrease the proteinuria by 50%. Renal hypoxia is the underlying causes of CK progression and associated hypertension. In hypoxic conditions, cells lack of oxygen, so that the cells carry out anaerobic metabolism or fermentation or Warburg effect. HBO therapy can assist in supplying oxygen more quickly at the cellular level (internal respiration), so that metabolism can re-process aerobically. Conclusion: HBO Therapy improves the patient's general condition in CKD with MetS, thereby preventing kidney disease complications. The effectiveness of HBOT for kidney disease still requires further research with a more frequent and longer treatment.
References
Al-Hamad, D., Raman, V., 2017. Metabolic syndrome in children and adolescents. Transl. Pediatr. 6, 397–407.
Bajaj, P., Chowdhury, S.K., Yucha, R., Kelly, E.J., Xiao, G., 2018. Emerging kidney models to investigate metabolism, transport, and toxicity of drugs and xenobiotics. Drug Metab. Dispos. 46, 1692–1702.
Bel, R. van der, Çaliskan, M., van Hulst, R.A., van Lieshout, J.J., Erik, E.S., Krediet, C.T.P., 2017. Blood pressure increase during oxygen supplementation in chronic kidney disease patients is mediated by vasoconstriction independent of baroreflex function. Front. Physiol. 8, 1–8.
Boykin, J. V., Baylis, C., 2007. Hyperbaric Oxygen Therapy Mediates Increased Nitric Oxide Production Associated With Wound Healing: A Preliminary Study. Adv Ski. Wound Care 20, 382–388.
Capó, X., Monserrat-Mesquida, M., Quetglas-Llabrés, M., Batle, J.M., Tur, J.A., Pons, A., Sureda, A., Tejada, S., 2023. Hyperbaric Oxygen Therapy Reduces Oxidative Stress and Inflammation, and Increases Growth Factors Favouring the Healing Process of Diabetic Wounds. Int. J. Mol. Sci. 24.
Choudhury, R., 2018. Hypoxia and hyperbaric oxygen therapy: A review. Int. J. Gen. Med. 11, 431–442.
Food and Drug Administration, 2006. Hyperbaric Oxygen Therapy.
Harrison, L.E., Giardina, C., Hightower, L.E., Anderson, C., Perdrizet, G.A., 2018. Might hyperbaric oxygen therapy (HBOT) reduce renal injury in diabetic people with diabetes mellitus? From preclinical models to human metabolomics. Cell Stress Chaperones 23, 1143–1152.
Heiden, M.G. Vander, Cantley, L.C., Thompson, C.B., 2009. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science (80-. ). 324, 1029–1033.
Kara, T., Hering, D., Zdrojewski, Z., Kro, E., Kucharska, W., Somers, V.K., Rutkowski, B., n.d. tonic chemoreflex activation in CRF pts.pdf 157–161.
Kidney Research UK, 2010. The Kidneys – a Basic Guide. Kidney Heal. Inf. 1, 13–25.
Kirby, J.P., Snyder, J., Schuerer, D.J.E., Peters, J.S., Bochicchio, G. V., 2019. Essentials of Hyperbaric Oxygen Therapy: 2019 Review. Mo. Med. 116, 176–179.
Laguardia, H.A., Hamm, L.L., Chen, J., 2012. The metabolic syndrome and risk of chronic kidney disease: Pathophysiology and intervention strategies. J. Nutr. Metab. 2012.
Mayer, B., Lameira da Costa, P.T., Echevarría-Guanilo, M.E., Silveira Kempfer, S., Da Silva Pieri, K.M., 2020. Kidney disease and hemodialysis: identification of blood biomarkers to detect heart failure and kidney failure. Rev. Colomb. Nefrol. 7, 44–54.
Medina-Leyte, D.J., Zepeda-García, O., Domínguez-Pérez, M., González-Garrido, A., Villarreal-Molina, T., Jacobo-Albavera, L., 2021. Endothelial dysfunction, inflammation and coronary artery disease: Potential biomarkers and promising therapeutical approaches. Int. J. Mol. Sci. 22.
Mohamed, A.S.E., Abdelrahman, A.A., Aly, U.F., Khaled, K.A., 2018. Hyperbaric oxygen therapy: A review. Eur. J. Clin. Pharm. 20, 263–269.
Pober, J.S., Min, W., Bradley, J.R., 2009. Mechanisms of endothelial dysfunction, injury, and death. Annu. Rev. Pathol. Mech. Dis. 4, 71–95.
Ramesh, S., Zalucky, A., Hemmelgarn, B.R., Roberts, D.J., Ahmed, S.B., Wilton, S.B., Jun, M., 2016. Incidence of sudden cardiac death in adults with end-stage renal disease: A systematic review and meta-analysis. BMC Nephrol. 17, 1–9.
Rosyanti, L., Hadi, I., Rahayu, D.Y.S., Wida, A.B.B., 2019. Theoritical Review Hyperbaric Oxygen Therapy/HBOT. HIJP Heal. Inf. Junal Penelit. 11, 182–205.
Sancak, E.B., Tan, Y.Z., Turkon, H., Silan, C., 2017. Attenuation of partial unilateral ureteral obstruction - induced renal damage with hyperbaric oxygen therapy in a rat model. Int. Braz J Urol 43, 946–956.
Sedlacek, M., Harlan, N.P., Buckey, J.C., 2021. Renal Effects of Hyperbaric Oxygen Therapy in Patients with Diabetes Mellitus: A Retrospective Study. Int. J. Nephrol. 2021.
Sen, C.K., 2009. Wound healing essentials: Let there be oxygen. Wound Repair Regen. 17, 1–18.
Sen, Suman, Sen, Sheuli, 2021. Therapeutic effects of hyperbaric oxygen: Integrated review. Med. Gas Res. 11, 30–33.
Shapira, R., Gdalyahu, A., Gottfried, I., Sasson, E., Hadanny, A., Efrati, S., Blinder, P., Ashery, U., 2021. Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients. Aging (Albany. NY). 13, 20935–20961.
Statistician, M., Applications, E., 2022. Article History Article. Scholar.Archive.Org 71, 143–148.
Steward, P., 1959. Physiology of the kidney. Updat. Anaesth. 13, 24–406.
Stirban, A., Gawlowski, T., Roden, M., 2014. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol. Metab. 3, 94–108.
Sureda, A., Batle, J.M., Martorell, M., Capó, X., Tejada, S., Tur, J.A., Pons, A., 2016. Antioxidant response of chronic wounds to hyperbaric oxygen therapy. PLoS One 11, 1–14.
Thomas, G., Sehgal, A.R., Kashyap, S.R., Srinivas, T.R., Kirwan, J.P., Navaneethan, S.D., 2011. Metabolic syndrome and kidney disease: A systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 6, 2364–2373.
Ustad, F., Ali, F.M., Ustad, T., Aher, V., Prasant, M.C., Suryavanshi, H., 2012. Uses of Hyperbaric Oxygen Therapy: A review. Evol. Med. Dent. Sci. 1, 892–906.
Wu, H.H., Huang, C.C., Chang, C.P., Lin, M.T., Niu, K.C., Tian, Y.F., 2018. Heat shock protein 70 (HSP70) reduces hepatic inflammatory and oxidative damage in a rat model of liver ischemia/reperfusion injury with hyperbaric oxygen preconditioning. Med. Sci. Monit. 24, 8096–8104.
Xiao, H., Shao, X., Gao, P., Zou, H., Zhang, X., 2022. Metabolic Syndrome Components and Chronic Kidney Disease in a Community Population Aged 40 Years and Older in Southern China: A Cross-Sectional Study. Diabetes, Metab. Syndr. Obes. 15, 839–848.
Xu, L., 2018. Analysis on Indoor Plant Landscapes in Interior Design Styles 232, 530–533.
Yuan, T., Yang, T., Chen, H., Fu, D., Hu, Y., Wang, J., Yuan, Q., Yu, H., Xu, W., Xie, X., 2019. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 20, 247–260.
Zhang, X., Lerman, L.O., 2017a. The metabolic syndrome and chronic kidney disease. Transl. Res. 183, 14–25.
Downloads
Published
License
Copyright (c) 2023 Hisnindarsyah Hisnindarsyah
This work is licensed under a Creative Commons Attribution 4.0 International License.
